Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1)

@inproceedings{LiuSullivan2011PooledSS,
  title={Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1)},
  author={Nancy Liu-Sullivan and Jianping Zhang and Amy Bakleh and John Marchica and Jinyu Li and Despina Siolas and Sylvie Laquerre and Yan Y. Degenhardt and Richard F. Wooster and Kenneth Chang and Gregory F. Hannon and Scott Powers},
  booktitle={Oncotarget},
  year={2011}
}
RNAi screening holds the promise of systemizing the search for combination therapeutic strategies. Here we performed a pooled shRNA library screen to look for promising targets to inhibit in combination with inhibition of the mitotic regulator polo-like kinase (PLK1). The library contained ~4,500 shRNAs targeting various signaling and cancer-related genes and was screened in four lung cancer cell lines using both high (IC80) and low (IC20) amounts of the PLK1 inhibitor GSK461364. The relative… CONTINUE READING
6 Citations
22 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and Oncotarget

  • Y Degenhardt, J Greshock, +13 authors B Weber
  • Mol Cancer Ther
  • 2010
Highly Influential
7 Excerpts

Similar Papers

Loading similar papers…